 |
0 Diseases |  |
92 Trials |
|
92 Trials |  |
4946 News |  |
| 12345678910111213...3940» |
- ||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal, Adverse events: Mining and influencing factors analysis of sacituzumab govitecan adverse drug event based on FAERS database. (Pubmed Central) - Nov 19, 2024
Common ADEs and the involved organ systems generally correspond with the prescribing information. Clinicians should be vigilant regarding unlisted ADEs when using sacituzumab govitecan, and close monitoring of laboratory indicators ensure patient medication safety.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal: Long-term efficacy and safety with sacituzumab govitecan in a patient with triple-negative breast cancer, multi-treated and high body mass index. (Pubmed Central) - Nov 18, 2024
The presented clinical case documents the efficacy and safety of long-term treatment with SG in an obese young woman with mTNBC who has already undergone multiple treatments. The patient is still responding after 20 months of treatment with good quality of life and social interactions.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal, BRCA Biomarker: Use of sacituzumab govitecan in frail patients with skin disease. (Pubmed Central) - Nov 18, 2024
The patient has no family history of breast cancer and does not have a mutation in the BRCA1/2 genes. In pathological history, only arterial hypertension under medical therapy with nebivolol.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal, Metastases: Sacituzumab govitecan nel trattamento delle pazienti pluritrattate affette da tumore della mammella triplo negativo metastatico. (Pubmed Central) - Nov 18, 2024
In pathological history, only arterial hypertension under medical therapy with nebivolol. No abstract available
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal: Sacituzumab govitecan in a triple-negative breast cancer patient journey: a cutting-edge story. (Pubmed Central) - Nov 18, 2024
Thanks to SG use within a multimodal patient journey, a sustained disease control along with a preserved quality of life was gained. Further real-world data is awaited to confirm these findings.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal: Activity of sacituzumab govitecan in skin metastases: description of a case. (Pubmed Central) - Nov 18, 2024
However, recent developments in molecular research and targeted therapy are opening up new perspectives with encouraging results for the treatment of this aggressive disease. The shared case wants to be an example: we will discuss the story of a 54 years old woman with extensive metastatic localizations in the skin that has obtained an important clinical response to therapy with sacituzumab govitecan, a conjugate antibody approved for the treatment of adult patients with metastatic triple negative breast cancer.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal: Sacituzumab govitecan in the second line treatment in a patient with triple-negative breast cancer with extensive locoregional recurrence. (Pubmed Central) - Nov 18, 2024
She continued treatment for a total of 9 cycles. The case confirms the clinical benefit and effectiveness of treatment with SG, in particular it underlines the good control of the disease characterized by a rapid and progressive course with exclusively locoregional extension and good control of symptoms with an improvement in quality of life.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal, Metastases: Sacituzumab govitecan nel trattamento di popolazioni speciali di pazienti con tumore mammario metastatico triplo negativo. (Pubmed Central) - Nov 18, 2024
The case confirms the clinical benefit and effectiveness of treatment with SG, in particular it underlines the good control of the disease characterized by a rapid and progressive course with exclusively locoregional extension and good control of symptoms with an improvement in quality of life. No abstract available
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal: Dual immunostimulatory CD73 antibody-polymeric cytotoxic drug complex for triple negative breast cancer therapy. (Pubmed Central) - Nov 17, 2024
However, the current ADC, sacituzumab govitecan, fails to overcome the crucial role of adenosine in the suppressive immune microenvironment characteristic of this "cold tumor"...Thus, it kills tumor cells with cytotoxic drugs, comprehensively regulates immunosuppression, and restores a durable immune response. This study proposes an antibody-polymeric drug complex with immunomodulatory and immunoagonist roles, offering new insights into TNBC treatment.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal, Metastases: Exposure-Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple-Negative Breast Cancer. (Pubmed Central) - Nov 17, 2024
Neutropenia was the only evaluated AE for which CAVGSG was significantly associated with grade ?3 events. The clinically meaningful efficacy and manageable safety achieved with SG 10?mg/kg on days 1 and 8 of every 21-day cycle dosing regimen supports the appropriateness of this clinical dosage in patients with mTNBC.
- || Trodelvy (sacituzumab govitecan-hziy) / Gilead
Review, Journal: Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook. (Pubmed Central) - Nov 16, 2024
Notably, the U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan (SG), a novel Trop2-targeted agent, for treating triple-negative breast cancer (TNBC) and refractory urothelial cancer, highlighting the significance of Trop2 in clinical oncology...We critically evaluate the current state by examining the relevant applications, diagnostic accuracy, therapeutic efficacy, and inherent limitations. Finally, we analyze the challenges impeding widespread clinical application and offer insights into strategies for advancing the field, thereby guiding future research endeavors.
- || Trodelvy (sacituzumab govitecan-hziy) / Gilead
Clinical, Review, Journal: Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials. (Pubmed Central) - Nov 15, 2024
The efficacy results showed a significantly greater clinical benefit with sacituzumab govitecan compared to standard chemotherapy in patients with triple-negative breast cancer. This drug will become a treatment of substantial impact in future treatment guidelines for this type of cancer.
- | Yutuo (zimberelimab) / Arcus Biosci, Gilead
Trial completion date, Trial primary completion date: ARIAN: Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (clinicaltrials.gov) - Nov 14, 2024
P2, N=129, Not yet recruiting, Sponsor: Fundaci
This drug will become a treatment of substantial impact in future treatment guidelines for this type of cancer. Trial completion date: Jun 2031 --> Nov 2031 | Trial primary completion date: Jun 2031 --> Nov 2031
- ||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Trial completion, Enrollment change: Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy (clinicaltrials.gov) - Nov 14, 2024
P4, N=25, Completed, Sponsor: Gilead Sciences
Trial completion date: Jun 2031 --> Nov 2031 | Trial primary completion date: Jun 2031 --> Nov 2031 Enrolling by invitation --> Completed | N=200 --> 25
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal, IO biomarker: Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. (Pubmed Central) - Nov 13, 2024
Enrolling by invitation --> Completed | N=200 --> 25 TACSTD2 expression is associated with key driver alterations and a more active immune microenvironment, suggesting possible combinatorial strategies with TROP2-targeting ADCs plus immunotherapy in various solid tumors.
- | Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Targeted and immunotherapy for the management of advanced urothelial carcinoma of the bladder. (Pubmed Central) - Nov 13, 2024
Pembrolizumab, with and without enfortumab, has demonstrated first-line activity, and avelumab is a key maintenance therapy after first-line treatment. The results of additional clinical trials should provide evidence to establish the exact role in therapy of each agent in patients with advanced disease.
- |||| Trodelvy (sacituzumab govitecan-hziy) / Gilead, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) (clinicaltrials.gov) - Nov 12, 2024
P2, N=348, Recruiting, Sponsor: West German Study Group
The results of additional clinical trials should provide evidence to establish the exact role in therapy of each agent in patients with advanced disease. Not yet recruiting --> Recruiting
- || Trodelvy (sacituzumab govitecan-hziy) / Gilead, Opdivo (nivolumab) / BMS
New P2 trial: Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence (clinicaltrials.gov) - Nov 12, 2024
P2, N=23, Not yet recruiting, Sponsor: University of California, Irvine
- || Trodelvy (sacituzumab govitecan-hziy) / Gilead
Enrollment closed, Metastases: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma (clinicaltrials.gov) - Nov 12, 2024
P1/2, N=56, Active, not recruiting, Sponsor: Institut f
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Analysis of the Clinical Impact of the Time to Reimbursement of New Oncology Drugs in Spain: A Case Study in Breast Cancer () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2342;
Two molecules were analysed: trastuzumab-deruxtecan in unresectable/metastatic HER2+ and HER2-low breast cancer (BC); and sacituzumab-govitecan in unresectable/metastatic triple-negative BC (mTNBC). These results provide possible metrics to quantify the benefits that can be obtained if time to availability of medicines for patients is cut short through planned public policies.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Talzenna (talazoparib) / Pfizer, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Comparative Analysis of HTA Decisions for Metastatic Breast Cancer Treatments in Nordic Countries () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2129;
These results provide possible metrics to quantify the benefits that can be obtained if time to availability of medicines for patients is cut short through planned public policies. Denmark exhibited more restrictive recommendations, with certain treatments like Trodelvy
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
The Economic Burden of Managing Grade ?3 AEs Following Treatment of Inoperable/Metastatic HR-Positive/HER2-Negative Breast Cancer in Italy, Spain and the United States () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1194;
Dato-DXd has an acceptable safety profile in HR+/HER2- BC and is associated with lower costs of managing G3AEs in Italy, Spain and the US compared with SG and ICC. The results should be interpreted with caution due to cross trial and country differences in AE management.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Comparative Clinical Effectiveness of Medicinal Products: Evaluation of International Criteria and Application to the NCPE HTA Process () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_73;
The rationale for how these criteria inform comparative clinical effectiveness ratings is often unclear, leading to heterogeneous conclusions across the methods. Further research will involve the application of these appraisal methods to other NCPE HTA appraisals.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Bridging Gaps in TNBC: Comparative Analysis of Patient Demographics and Treatment Patterns Between Australia and EU4+UK Countries (Halls 1 & 2) - Nov 3, 2024 - Abstract #COSA2024COSA_318;
This study highlights disparities in treatment funding, particularly in the UK and therapy utilisation between Australia and EU4+UK countries, underscoring the need for aligned treatment protocols and equitable access to care. Bridging these gaps will facilitate progress in global cancer care, breaking down disparities and potentially improving outcomes for TNBC patients worldwide.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Triple Negative Breast Ca- A Therapeutic Update and Case Study presentation (Arena 1B) - Nov 3, 2024 - Abstract #COSA2024COSA_233;
Despite this, the prognosis for patients with metastatic TNBC remains poor compared to advanced hormone positive disease. Further research into predictive and prognostic biomarkers as well as utilising differing combinations of chemotherapy, immunotherapy and ADCs are currently being investigated to further improve patient outcomes.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Single-center retrospective cohort study evaluating neutropenia and growth factor use with sacituzumab govitecan in patients with HR+/HER2- and triple negative metastatic breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2256;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Best response to antibody-drug conjugates (ADCs), sacituzumab govitecan and trastuzumab deruxtecan, based on organ site of metastatic breast cancer (MBC) involvement (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2131;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Genomic markers of sacituzumab govitecan (SG) response in metastatic triple-negative breast cancer and hormone receptor-positive breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1972;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Strategies for premedication and neutropenia prophylaxis in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1604;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Excellent and Prolonged Response to Sacituzumab-govitecan in Triple Negative mBC (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1599;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Real world data with standard (SD) and reduced dose (RD) sacituzumab-govitecan (SG) in metastatic triple negative (TNBC) and ER+/HER2- metastatic breast cancer (mBC) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1404;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Results of the cohort w/ central nervous system (CNS) metastasis in the real-world evidence observational study SACISUR, patients treated w/ Sacituzumab-Govitecan (SG) in triple neg metastatic breast cancer (mTNBC) clinical practice in the south (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1398;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
SARELIFE study: Safety and efficacy of Sacituzumab Govitecan (SG) in pretreated metastatic triple negative breast cancer (mTNBC): a multicentric, real-life study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1397;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Real-world use of sacituzumab govitecan (SG) in the management of metastatic triple-negative breast cancer (mTNBC) through a Canadian Patient Support Program (PSP) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1395;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
SERIES: SEquencing Sacituzumab Govitecan (SG) AfteR Trastuzumab Deruxtecan (T-DXd) In ER+/HER2 LOW MetaStatic Breast Cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1358;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Clinical Activity of Sacituzumab Govitecan in Metastatic Triple Negative and Hormone Receptor Positive, HER-2 Negative Breast Cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1277;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Real-World Treatment Patterns and Clinical Outcomes of Sacituzumab Govitecan in HER2 negative metastatic breast cancer patients in China (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1265;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Sacituzumab Govitecan in Metastatic Breast Cancer: Impact of Age and BRCA Mutational Status in a Real-World Cohort (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1259;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Multicenter retrospective cohort study of the sequential use of antibody drug conjugates trastuzumab deruxtecan & sacituzumab govitecan in patients with HER2 low metastatic breast cancer: a subgroup analysis of next generation sequencing results. (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1205;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Generation of Sacituzumab Govitecan Resistant Breast Cancer Models (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1118;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
SACISUR, results of a real-world evidence observational study of the use of Sacituzumab-Govitecan (SG) in triple negative metastatic breast cancer (mTNBC) clinical practice in the south of Spain. (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_897;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Keytruda (pembrolizumab) / Merck (MSD)
Correlation of TROP2 expression with outcomes of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer: an exploratory analysis from the phase II SACI-IO HR+ trial (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_889;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Real-world safety of sacituzumab govitecan in patients with advanced triple receptor-negative breast cancer in a tertiary centre in the United Kingdom (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_848;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Health-Related Quality of Life with Sacituzumab Govitecan versus Treatment of Physician's Choice in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: A Meta-Analysis of TROPiCS-02 and EVER-132-002 Trials (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_826;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Metabolic tumor burden measured by [18F]FDG PET/CT and outcomes of patients with HER2-negative mBC treated with sacituzumab govitecan or trastuzumab deruxtecan (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_822;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST) Analysis of Sacituzumab Govitecan vs Chemotherapy in Previously Treated Patients with HR+/HER2 (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_634;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Extreme response to sacituzumab-govitecan in a patient with metastatic triple-negative breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_612;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Characteristics associated with sacituzumab govitecan response in the real-world setting (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_524;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses of Sacituzumab Govitecan (SG) in Japanese Patients (pts) with Metastatic Triple-Negative Breast Cancer (mTNBC) and other Advanced Solid Tumors (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_519;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Management of Neutropenia and Effectiveness of Sacituzumab Govitecan (SG) in Patients (pts) With Metastatic Triple-Negative Breast Cancer (mTNBC) Treated in Real-World Settings in the United States (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_511;